In 2025 it will be 20 years since the Centre for Psychedelic Research began its study of psychedelic drugs in humans, first at Bristol University and then since 2008 at Imperial College London. What started out as an imaging study of the brain mechanisms of psilocybin in collaboration with Robin Carhart-Harris and Amanda Feilding has turned into a life changing body of research that has encompassed many hundreds of colleagues: doctors psychologists and neuroscientists.
David Nutt
Patil Armenian, Benjamin Hatten
VA researchers Dr. Chris Stauffer and Dr. Amy Lehrner share insights on their pioneering studies of psychedelic-assisted therapy for PTSD, depression, and substance use in veterans, highlighting clinical models, set and setting, and peer support involvement.
Amy Lehrner, Christopher “Chris” Stauffer
Dráulio Araújo, Fernanda Palhano-Fontes, Marcelo Leite, Nicole Galvão-Coelho
Rupika Delgoda, Kimberly Foster, William Irvine, Isaac Morrison
Depression remains a major unmet medical need globally, with current medications often providing inadequate relief and leading to high costs. Psychedelic therapies, like psilocybin, show promise in revolutionizing mental health
Charles Raison
Dr. Sloshower presents results from a psilocybin-assisted therapy study for major depression, showing larger antidepressant effects than placebo, with lasting mood improvements. Dr. Kilpatrick discusses longitudinal case studies.
Jordan Sloshower, Stephanie Kilpatrick
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Psychedelics are studied for psychiatric disorders; research emphasizes 'set and setting.' Study explores psychosocial factors in psychedelic use, linking communal experiences to improved mental health outcomes.
Hannes Kettner
Dr. Harris shares insights from interviews with women elders guiding long-term underground psychedelic journeys, focusing on themes like self-healing, apprenticeship, and relationships with medicines. These priestesses offer an alternative perspective
Rachel Harris
Candace Oglesby, Courtney Watson, Monica Wade, Victoria Leftridge
Regulators discuss state frameworks for psychedelic healing to ensure success, equity, and safety in the industry. Various perspectives on the new programs are explored.
Dominique D Mendiola
The official Opening Plenary of Psychedelic Science 2025. This 90-minute session brings the full community together to mark the start of the conference. No other programming is scheduled during this time—we invite everyone to be part of this collective moment.
Rick Williams, Ismail Lourido Ali, Betty Aldworth, Rick Doblin, Vicky Dulai
Dr. Smith and Dr. Jones explore the latest advancements in quantum computing during their presentation at the Tech Summit 2023.
Bia Labate
Dr. Dölen presents evidence linking psychedelics to reopening the social reward learning critical period, suggesting a shared mechanism across these drugs. This metaplastic restoration of oxytocin-mediated long-term depression may have
Roland R. Griffiths, PhD, honored at Psychedelic Science Conference. Pioneered psilocybin research, founded Johns Hopkins Center for Psychedelic and Consciousness Research, influencing a new wave of researchers.
William Richards, Theresa Carbonaro, Katherine Bonson
Hardman provides a quick overview of the emerging psychedelic sector, covering financial, research, and policy landscapes with data visuals. He also explores unanswered questions about the sector's future.
Josh Hardman
Indigenous plant medicines and practices are threatened by colonialism, extraction, and climate change. Supporting traditional Indigenous Medicine conservation directly supports climate and biodiversity conservation.
Miriam Volat, Mona Polacca, Chief Nixiwaka Biraci Yawanawa
Panel explores challenges of managing expectations and risks in psychedelic-assisted therapy amid growing media coverage. Participants, patients, and practitioners often lack information on risks.
David B Yaden, Xiaojue Hu
Manoj Doss discusses psychedelic impact on episodic memories, highlighting FLUX theory. Fred Barrett explores psychedelic therapy's potential for lasting shifts in psychological and cognitive flexibility across disorders.
Frederick Barrett, Manoj K. Doss
Therapists and religious professionals discuss ethical considerations in using psychedelics with vulnerable individuals, emphasizing the need for integrity and accountability in the psychedelic profession.
Cedar Barstow, Jennifer C Jones
Traditional medicines and indigenous communities attract outsiders, but interactions can unintentionally harm. How can outsiders respectfully engage and contribute to traditional cultures?
Sandor Iron Rope, Claude Guislain, Sutton King
Session explores health equity challenges and opportunities in mainstream psychedelic therapy, focusing on experiences of 3 women of color. Topics include overcoming inequity, cultural trauma, power dynamics, and ancestral healing.
Claudia Cuentas, Sara Reed, Deran Young
Panel of experts explores psychedelics' role in conflict resolution, restorative justice, and peace-building. Discussion includes research, experiences, and ethical considerations for integrating psychedelics into transformative processes.
Young elders explore merging tradition and modernity, addressing political, ecological, and epistemological challenges. Discussion aims to balance tradition and progress in a changing world.
Charlotte James
Psychedelic Science 2023 features opening land acknowledgement and addresses by Rick Doblin, Governor Rick Perry, and Governor Jared Polis.
Gov. Rick Perry, Governor Jared Polis, Maya Padilla
Key themes at Psychedelic Science 2023 included examining access, affordability, and reciprocity. The community was urged to address the impact of colonial systems on Indigenous communities and ensure equity for
Marwan and Noam, Snow Raven
Michael Pollan, an influential author, sparked interest in psychedelic research with his book "How to Change Your Mind." Bob Jesse, a key figure in the resurgence of psychedelics, has made
Robert Jesse, Michael Pollan
Blake Mycoskie founded TOMS Shoes with the One for One® model, providing shoes to children in need globally. He also co-founded Madefor to promote positive habits and practices.
Joe Green, Blake Mycoskie
Vicky Dulai of Compassion For Addiction moderates a discussion with Amy Emerson of MAPS Public Benefit Corporation and Rachel Yehuda of Icahn School of Medicine on leadership in the psychedelic
Rachel Yehuda
Therapists and clinicians must collaborate to integrate psychedelic therapy into the behavioral health system, engaging professional organizations, providers, payers, and policymakers. Key steps for integration and clinician involvement will be
David Esselman, Sarah Abedi
Dr. Anne Wagner and Dr. Michael Mithoefer discuss therapeutic potential of MDMA for couples, sharing insights from their MDMA-assisted couples therapy trials and ongoing research with Dr. Chandra Khalifian and
Chandra Khalifian, Leslie Morland, Kayla Knopp
Psychedelic-assisted therapies for adolescents are discussed, including the use of ketamine for treatment-resistant depression and the need for further studies and careful consideration of risks. Traditional use of plant medicines
Corine de Boer, Rebecca Kronman, Glauber Assis
Clinical trials show potential of psychedelics for psychiatric treatment, but studies note varied responses. Unclear clinical mechanism discussed in talk on neurobiology and optimizing psychedelic therapy.
Panel explores challenges of managing expectations and risks in psychedelic-assisted therapy amid growing media coverage. Participants, patients, and practitioners often lack information on risks.
David B Yaden, Xiaojue Hu
Session explores health equity challenges and opportunities in mainstream psychedelic therapy, focusing on experiences of 3 women of color. Topics include overcoming inequity, cultural trauma, power dynamics, and ancestral healing.
Claudia Cuentas, Sara Reed, Deran Young
Psychedelic-assisted therapies for adolescents are discussed, including the use of ketamine for treatment-resistant depression and the need for further studies and careful consideration of risks. Traditional use of plant medicines
Corine de Boer, Rebecca Kronman, Glauber Assis
Young elders explore merging tradition and modernity, addressing political, ecological, and epistemological challenges. Discussion aims to balance tradition and progress in a changing world.
Charlotte James
Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case
Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper
Panel explores challenges of managing expectations and risks in psychedelic-assisted therapy amid growing media coverage. Participants, patients, and practitioners often lack information on risks.
David B Yaden, Xiaojue Hu
Indigenous plant medicines and practices are threatened by colonialism, extraction, and climate change. Supporting traditional Indigenous Medicine conservation directly supports climate and biodiversity conservation.
Miriam Volat, Mona Polacca, Chief Nixiwaka Biraci Yawanawa
Traditional Indigenous medicines like Ayahuasca have become global phenomena. Psychedelic companies are exploring them for drug development, posing challenges for Indigenous and ceremonial communities.
Vicky Dulai of Compassion For Addiction moderates a discussion with Amy Emerson of MAPS Public Benefit Corporation and Rachel Yehuda of Icahn School of Medicine on leadership in the psychedelic
Rachel Yehuda
Philanthropy and investors can support crucial psychedelic research and initiatives beyond commercial interests to shape the field and promote equity and social value in the psychedelic economy.
Sandy Samberg
Address delves into peyote's historical, cultural, and colonial impact, challenging dominant narratives and exploring paths for cultural preservation and religious freedom. Speakers illuminate untold narratives and complexities.
